Management of atrial fibrillation in the emergency department and following acute myocardial infarction

Canadian Journal of Cardiology

Volumn 21, Issue SUPPL. B, 2005, Pages

  Heilbron, Brett ^a   Klein, George J ^b   Talajic, Mario ^c   Guerra, Peter G ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Anticoagulation; Atrial fibrillation; Electrical cardioversion; Emergency department; Myocardial infarction

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; CONFERENCE PAPER; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HOSPITAL ADMISSION; HUMAN; PHYSICIAN; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; EMERGENCY SERVICE, HOSPITAL; EMERGENCY TREATMENT; HUMANS; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES;

EID: 34247344577     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation. J Am Coll Cardiol 1992;19:41A. (Abst)
2. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-41.
3. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997;127:281-4.
4. Prystowsky EN. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol 1994;17(Suppl 2):II7-10.
5. Wakai A, O'Neill JO. Emergency management of atrial fibrillation. Postgrad Med J 2003;79:313-9.
6. Fuster V, Ryden LE, Asinger RW, et al; American College of Cardiology; American Heart Association; European Society of Cardiology; North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852-923.
7. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985;254:3449-53.
8. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004;164:55-60.
9. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 1987;106:503-6.
10. Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J 1988;9:279-83.
11. Jordaens L, Trouerbach J, Calle P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 1997;18:643-8.
12. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997;18:649-54.
13. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88-90.
14. Ang EL, Chan WL, Cleland JG, et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J 1990;64:256-60.
15. Leung DY, Davidson PM, Cranney OB, Walsh WF. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol 1997;79:626-9.
16. Stollberger C, Chnupa P, Kronik G, et al; ELAT Study Group. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Intern Med 1998;128:630-8.
17. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998;128:639-47.
18. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998;31:1622-6.
19. Jones EF, Calafiore P, McNeil JJ, Tonkin AM, Donnan GA. Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol 1996;78:425-9.
20. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol 1994;24:755-62.
21. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
22. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
23. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
24. Segal JB, McNamara RL, Miller MR, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev 2001:CD001938.
25. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331:785-91.
26. Kim MH, Conlon B, Ebinger M, et al. Clinical outcomes and costs associated with a first episode of uncomplicated atrial fibrillation presenting to the emergency room. Am J Cardiol 2001;88:A7,74-6.
27. Michael JA, Stiell IG, Agarwal S, Mandavia DP. Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 1999;33:379-87.
28. Koenig BO, Ross MA, Jackson RE. An emergency department observation unit protocol for acute-onset atrial fibrillation is feasible. Ann Emerg Med 2002;39:374-81.
29. Crozier I, Melton I, Pearson S. Management of atrial fibrillation in the emergency department. Intern Med J 2003;33:182-5.
30. Zimetbaum PJ, Schreckengost VE, Cohen DJ, et al. Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. Am J Cardiol 1999;83:450-2,A9.
31. Mulcahy B, Coates WC, Henneman PL, Lewis RJ. New-onset atrial fibrillation: When is admission medically justified? Acad Emerg Med 1996;3:114-9.
32. Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. " Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients. N Engl J Med 1963;269:325-31.
33. Levy S, Lauribe P, Dolla E, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992;86:1415-20.
34. Alt E, Ammer R, Schmitt C, et al. A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion. Eur Heart J 1997;18:1796-804.
35. Page RL, Kerber RE, Russell JK, et al; BiCard Investigators. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: The results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 2002;39:1956-63.
36. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation: Comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000;101:1282-7.
37. Niebauer MJ, Chung MK, Wilkoff BL, et al. Success rate of the rectilinear biphasic waveform in atrial cardioversion in a large cohort of patients. Circulation 2000;102:574F. (Abst)
38. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.
39. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: Prevalence and outcomes. Circulation 2000;101:969-74.
40. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: The GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:406-13.
41. Fuster V, Ryden LE, Asinger RW, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50.
42. Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: A community-wide perspective. Am Heart J 2002;143:519-27.
43. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart 2001;86:527-32.
44. Waldecker B. Atrial fibrillation in myocardial infarction complicated by heart failure: Cause or consequence? Eur Heart J 1999;20:710-2.
45. Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: The GUSTO-III experience. Am Heart J 2000;140:878-85.
46. Wong CK, White HD, Wilcox RG, et al; GUSTO-III Investigators. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: The GUSTO-III experience. Global use of strategies to open occluded coronary arteries. Heart 2002;88:357-62.
47. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis SA, Zaga AK, Nanas JN. Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. Cardiovasc Drugs Ther 2001;15:155-60.
48. Zaqqa M, Afshar H, Rasekh A, Khoshnevis R, Vaughn WK, Massumi A. Predictors of conversion to sinus rhythm using ibutilide for atrial fibrillation or flutter. Am J Cardiol 2000;85:112-4,A9.
49. Varriale P, Sedighi A. Acute management of atrial fibrillation and atrial flutter in the critical care unit: Should it be ibutilide? Clin Cardiol 2000;23:265-8.
50. Hennersdorf MG, Perings SM, Zuhlke C, et al. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. Intensive Care Med 2002;28:925-9.
51. Harg P, Madsen S, Amlie JP. [Severe ibutilide-induced arrhythmia in patients with heart failure.] Tidsskr Nor Laegeforen 2001;121:2834-5.
52. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-12.
53. Al-Dashti R, Sami M. Dofetilide: A new class III antiarrhythmic agent. Can J Cardiol 2001;17:63-7.
54. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001;104:292-6.
55. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.